Spruce Biosciences, a Phase 2 biotech developing novel therapies for rare endocrine disorders, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The company's lead candidate, tildacerfont, is being developed for classic congenital adrenal hyperplasia (CAH). The company has initiated a Phase 2b trial in adult patients with classic CAH with poor disease control and anticipates topline results in the 4Q21 or the 1Q22. It has also initiated a second Phase 2b trial in adult patients with classic CAH with good disease control and anticipate topline results in the 1H22.
The Daly City, CA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol SPRB. Spruce Biosciences filed confidentially on August 7, 2020. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Rare disease biotech Spruce Biosciences files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.